Your browser is no longer supported. Please, upgrade your browser.
TEVA Teva Pharmaceutical Industries Limited daily Stock Chart
Teva Pharmaceutical Industries Limited
Index- P/E19.20 EPS (ttm)1.73 Insider Own2.70% Shs Outstand1.03B Perf Week-2.09%
Market Cap34.21B Forward P/E6.84 EPS next Y4.86 Insider Trans0.00% Shs Float1.01B Perf Month-9.13%
Income1.59B PEG17.34 EPS next Q1.36 Inst Own57.20% Short Float1.92% Perf Quarter-22.63%
Sales20.29B P/S1.69 EPS this Y-48.90% Inst Trans-0.10% Short Ratio1.89 Perf Half Y-38.22%
Book/sh32.18 P/B1.03 EPS next Y-5.23% ROA2.40% Target Price45.09 Perf Year-44.86%
Cash/sh1.52 P/C21.85 EPS next 5Y1.11% ROE5.70% 52W Range33.46 - 62.53 Perf YTD-8.33%
Dividend1.36 P/FCF- EPS past 5Y-13.10% ROI5.70% 52W High-46.85% Beta0.60
Dividend %4.09% Quick Ratio0.60 Sales past 5Y4.00% Gross Margin55.80% 52W Low-0.69% ATR0.81
Employees42888 Current Ratio0.90 Sales Q/Q15.30% Oper. Margin15.90% RSI (14)30.44 Volatility1.56% 2.16%
OptionableYes Debt/Eq1.17 EPS Q/Q194.70% Profit Margin7.80% Rel Volume0.82 Prev Close33.47
ShortableYes LT Debt/Eq1.05 EarningsFeb 14 BMO Payout77.90% Avg Volume10.32M Price33.23
Recom2.30 SMA20-6.79% SMA50-9.82% SMA200-29.31% Volume8,447,000 Change-0.72%
Jan-20-17Downgrade JP Morgan Overweight → Neutral
Jan-09-17Downgrade Wells Fargo Outperform → Market Perform
Jan-06-17Downgrade Maxim Group Buy → Hold $49 → $41
Jan-03-17Reiterated Maxim Group Buy $52 → $49
Dec-07-16Resumed Oppenheimer Outperform
Nov-16-16Reiterated RBC Capital Mkts Outperform $58 → $51
Nov-16-16Reiterated Mizuho Neutral $45 → $40
Nov-16-16Reiterated Maxim Group Buy $72 → $52
Nov-16-16Reiterated Deutsche Bank Buy $68 → $54
Nov-16-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-16-16Downgrade Jefferies Buy → Hold $69 → $40
Nov-14-16Resumed Barclays Equal Weight $46
Nov-14-16Reiterated RBC Capital Mkts Outperform $71 → $58
Nov-07-16Downgrade BofA/Merrill Buy → Neutral
Nov-04-16Downgrade HSBC Securities Buy → Hold
Oct-31-16Upgrade Credit Suisse Neutral → Outperform
Oct-24-16Downgrade Mizuho Buy → Neutral $64 → $45
Aug-25-16Reiterated Mizuho Buy $70 → $64
Aug-08-16Reiterated Mizuho Buy $75 → $70
Jul-18-16Upgrade HSBC Securities Hold → Buy
Jan-22-17 06:42AM  3 Incredibly Cheap High-Yield Dividend Stocks at Motley Fool
Jan-20-17 12:59PM  JP Morgan Downgrades Teva at Investopedia
06:22AM  Teva Pharma downgraded by JP Morgan
Jan-19-17 02:13PM  Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Secures FDA Approval For Vantreal ER at Insider Monkey
08:51AM  Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
Jan-18-17 11:02AM  Teva's Pain Drug Gets Approved By The FDA at Investopedia
11:00AM  FDA approves Teva's abuse-deterrent painkiller at
10:40AM  Orphan Drugs Among 2015's Top 10 Best-Selling Medications
08:00AM  Teva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets Formulated with Proprietary Abuse Deterrence Technology Business Wire
Jan-17-17 05:20PM  10 Dividend Growth Stocks That Simply Print Money at Kiplinger
Jan-16-17 08:38AM  5 Trump-Proof Pharma Dividends Up To 5.3% at Forbes
07:39AM  Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
Jan-13-17 07:30AM  Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference
07:09AM  Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
Jan-12-17 04:18PM  Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva
03:39PM  Patent Victory Secures Lilly Hold on Cancer Drug Until 2022
12:26PM  Eli Lilly's stock rallies after appeals court upholds favorable patent ruling at MarketWatch
09:36AM  Lilly Jumps After Lung Cancer Drug Patent Upheld at Bloomberg
07:45AM  These 3 stocks may be the only true value plays left at MarketWatch
Jan-11-17 04:21PM  Drug Stocks Tank As Trump Vows To Attack High Drug Prices
04:04PM  Macys, Teva Join Wednesdays 52-Week Low Club
11:05AM  New Strong Sell Stocks for January 11th
Jan-10-17 07:45AM  What's behind surge of puts in Teva
Jan-09-17 06:21PM  Teva Stock Gets Axed By Analysts at Investopedia
01:56PM  Analysts Slash Teva Targets Following Disappointing Guidance at
01:03PM  3 Top Dividend Stocks Selling for a Discount This Winter at Motley Fool
11:21AM  Teva Pharmaceutical Industries Ltd -- Moody's: Operating Headwinds Weigh On Teva's 2017 Deleveraging Plans -- A Credit Negative at Moody's
10:10AM  Stock Market News for January 09, 2017
08:11AM  Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
07:39AM  Teva Falls on Disappointing 2017 Sales & Earnings Guidance
07:30AM  Teva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European Commission Approval Business Wire
Jan-07-17 09:00AM  How to Trade the Week's Most Active Stocks -- Apple, AT&T, Chesapeake Energy and More
Jan-06-17 04:01PM  Teva to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire -7.53%
03:46PM  Here's Why Teva Pharmaceuticals is Plunging Today
03:26PM  Teva Pharmaceutical: What the Heck Does 'Focused on Execution' Mean Anyway? at
03:26PM  Is Teva a Value Trap? at Investopedia
12:35PM  Why Teva Pharmaceuticals Shares Are Losing Steam at TheStreet
11:26AM  Here's Why Teva Shares Are Plummeting
11:19AM  Teva's 2017 revenue, profit forecasts miss as launch delays weigh
11:00AM  Teva provides financial forecast with a caveat at
09:48AM  UPDATE 1-Teva forecasts 2017 revenue, profit below estimates
09:47AM  Teva forecasts 2017 revenue, profit below estimates
08:12AM  [$$] Teva Gives Downbeat Earnings Forecast at The Wall Street Journal
07:51AM  Teva Pharmaceutical issues 2017 guidance that is below expectations at MarketWatch
07:41AM  4 Factors That Sent Teva Pharmaceutical Industries Ltd. Sliding 45% in 2016 at Motley Fool
07:30AM  Teva Provides 2017 Financial Outlook Business Wire
Jan-05-17 04:41PM  Mylan, Novartis, Hikma Take On GSK In Generic Asthma Battle
04:01PM  Teva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017 Business Wire
10:30AM  Six Happenings You Won't Want to Miss When 'Frisco Takes Center Stage in Health Care
07:15AM  Teva's Range of Products, Reach Make It a Solid Value Play in the Drug Sector
06:45AM  What Pharma and Healthcare Investors Should Watch For at JPM Next Week
Jan-04-17 02:06PM  [$$] Teva: Tempering the 2017 Outlook at
07:28AM  Now's the Time to Embrace This Unloved Drug Stock
Jan-03-17 04:06PM  Guggenheim Removes Teva From Best Ideas List at Investopedia
03:44PM  GPM Reminds Investors of the January 5 Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Limited Business Wire
01:30PM  Biogen boosts price of top MS drugs, analyst says at
10:14AM  Migraine Biologics Drugs Has Blockbuster Potential at Investopedia
09:15AM  Meet Miami's Renaissance Billionaire at Forbes
Jan-02-17 05:58PM  Teva: Good Value, Questionable Management?
Dec-31-16 05:02PM  4 Stocks Reach Their 3-Year Low Prices
Dec-30-16 11:15AM  3 Sleeper Biotechs That Could Bounce Back Strong in 2017
10:30AM  January 5 Deadline Alert: Law Offices of Howard G. Smith Reminds Teva Pharmaceutical Industries Limited Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm Business Wire
08:57AM  Securities Law Firms Seeking Lead Plaintiffs In Class Action Suit Against Teva Pharmaceutical Industries Ltd (ADR) (TEVA) at Insider Monkey
08:30AM  10 Good Stocks That Are Flying Under the Radar at Kiplinger
Dec-29-16 10:34AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses in Excess of $1,000,000 of Class Action Against Teva Pharmaceutical Industries Limited (TEVA) and Lead Plaintiff Deadline - January 5, 2017 Accesswire
10:10AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Teva Pharmaceutical Industries Limited (TEVA) & Lead Plaintiff Deadline - January 5, 2017 GlobeNewswire
07:00AM  Healthcare: What Does a Trump Administration Mean for Healthcare Stocks? at Morningstar
Dec-28-16 04:44PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $250,000 Investing in Teva Pharmaceutical Industries Ltd. to Contact the Firm Before Imminent Lead Plaintiff Deadline Accesswire
03:40PM  Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Agrees To Settle With The SEC Over Corruption Charges at Insider Monkey
03:06PM  DEADLINE ALERT: Brower Piven Reminds Investors Of The January 5, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Teva Pharmaceutical Industries Limited To Contact The Firm GlobeNewswire
10:25AM  Short Interest Rises in Major Pharma
Dec-27-16 06:34PM  Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited Business Wire
12:40PM  Teva Agrees to Pay Over $500 Million for FCPA Violations
11:00AM  Biotech Poised for Rebound
09:00AM  TEVA REMINDER: Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important January 5 Deadline in Class Action Filed by Firm- TEVA GlobeNewswire
Dec-23-16 04:54PM  December Delivers Again for FCPA Enforcement Watchers at The Wall Street Journal
02:20PM  US Accelerates Pursuit Of Companies For FCPA Violations at Forbes
10:11AM  Allergan Outlook Improves On Good Trial For Colon Drug: Credit Suisse
08:16AM  Teva Settles Foreign Bribery Charges with U.S. Government
12:10AM  [$$] Teva Settles Foreign Corruption Probe for $519 Million at The Wall Street Journal
Dec-22-16 04:08PM  Drastic Drug-Price Action No Trump Card, Says Needham
01:56PM  Teva Spikes After Settling On Corruption Probe at Investopedia
01:52PM  Teva Pharmaceutical: It Ain't Over 'Til It's Over at
01:21PM  [$$] Teva agrees $519m settlement of anti-bribery charges at Financial Times
12:59PM  Teva to pay U.S. government $519 million over foreign bribery charges Reuters
12:54PM  Teva to pay U.S. government $519 mln over foreign bribery charges Reuters
11:44AM  These Billionaire Michael Prices Stock Picks Can Destroy Your Portfolio at Insider Monkey
11:35AM  [$$] Teva Settles Foreign Corruption Probe for $519 Million at The Wall Street Journal
11:30AM  Teva Will Pay $519 Million to Settle Foreign Bribery Charges; Shares Jump
11:00AM  Teva to pay $519M to resolve bribery allegations at
10:55AM  SEC, DOJ fine Teva Pharmaceutical $519 million to settle foreign bribery charges at MarketWatch
10:51AM  Teva agrees to pay more than $519 million to settle bribe allegations: DoJ Reuters
10:49AM  Teva agrees to pay more than $519 mln to settle bribe allegations - DoJ Reuters
09:57AM  Teva to pay US government $519 mln over foreign bribery charges Reuters
09:15AM  Teva Reaches Settlement with Government on FCPA Business Wire
Dec-21-16 01:06PM  Allergan: Why LifeCell Deal is a 'Christmas Miracle!' at
08:16AM  Allergan to Buy LifeCell to Boost Regenerative Medicine Suite
Dec-20-16 10:55AM  Impax Searches for a New CEO
07:36AM  3 Stocks the Smartest Investors are Buying Right Now at Motley Fool
Dec-19-16 05:31PM  Analysts Mixed on Health Care Stocks in the New Year
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company's Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The company's Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women's health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson's disease; Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders; Fentora/Effentora for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Zecuity, a prescription transdermal system for the acute treatment of migraine with or without aura in adults. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Granix, Trisenox, Synribo, Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim, and Trisenox products in the oncology market. This segment also offers a portfolio of products in the women's health category, which includes ParaGard, Plan B One-Step, OTC/Rx, Zoely, Seasonique, and Ovaleap, as well as other products. Teva Pharmaceutical Industries Limited has collaboration arrangements with Takeda Pharmaceutical Company Limited, Procter & Gamble Company, Intel, and Regeneron Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.